The association between Matrix Metallo-proteinases-9 (MMP-9) gene family polymorphisms and risk of Coronary Artery Disease (CAD): a systematic review and meta-analysis

Hassanzadeh-Makoui, Reza; Razi, Bahman; Aslani, Saeed; Imani, Danyal; Tabaee, Seyedeh Samaneh

doi:10.1186/s12872-020-01510-4

Table 1 Characteristics of studies included in meta-analysis of overall CAD

From: The association between Matrix Metallo-proteinases-9 (MMP-9) gene family polymorphisms and risk of Coronary Artery Disease (CAD): a systematic review and meta-analysis

Study author	Year	Country	Ethnicity	Study design	Type of CAD	Total cases/controls	Age Case / Control (Mean)	Genotyping method	Quality score
MMP-9 (C1562T)
Pollanen et al.	2001	Finland	European	Case-control	ACS	109 / 167	33–69 / 33–69	PCR-RFLP	6
Wang et al.	2001	Australia	Oceania	Case-control	Stable	619 / 169	57.7 ± 0.5 / NR	PCR-RFLP	7
Cho et al.	2002	Korea	Asian	Case-control	Stable	63 / 134	NR / NR	PCR-RFLP	5
Kim et al.	2002	Korea	Asian	Case-control	Stable	131 / 117	61.3 ± 7.9 / 59.3 ± 8.5	PCR-RFLP	6
Jones et al.	2002	New Zealand	European	Case-control	Stable	414 / 203	71.7 ± 7.6 / 70.8 ± 8.0	PCR-RFLP	8
Tang et al.	2005	China	Asian	Case-control	ACS	101 / 105	NR / NR	PCR-RFLP	5
Chen et al.	2005	China	Asian	Case-control	ACS	78 / 81	NR / NR	PCR-RFLP	5
Meng et al.	2006	China	Asian	Case-control	Stable	117 / 99	NR / NR	PCR-RFLP	5
Nuzzo et al.	2006	Italy	European	Case-control	ACS	49 / 123	NR / NR	PCR-RFLP	5
Chen et al.	2007	China	Asian	Case-control	Stable	150 / 70	NR / NR	PCR-RFLP	5
Nanni et al.	2007	Italy	European	Case-control	ACS	200 / 201	47.8 ± 6.2 / 47.0 ± 5.5	PCR-RFLP	7
Wang et al.	2007	China	Asian	Case-control	ACS	245 / 204	NR / NR	PCR-RFLP	8
Zhang et al.	2008	China	Asian	Case-control	ACS	92 / 95	NR / NR	PCR-RFLP	5
Koh et al.	2008	Korea	Asian	Case-control	ACS	206 / 173	61.1 ± 11.8 / 58.3 ± 11.8	PCR-RFLP	6
Alp et al.	2009	Turkey	European	Case-control	Stable	146 / 122	59.30 ± 9.1 / 57.30 ± 9.7	PCR-RFLP	6
Wu et al.	2009	China	Asian	Case-control	ACS	2517 / 689	NR / 60.42 ± 9.07	PCR-RFLP	8
Gao et al.	2010	China	Asian	Case-control	Stable	96 / 78	NR / NR	PCR-RFLP	5
Fallah et al.	2010	Iran	Asian	Case-control	Stable	145 / 157	58.49 ± 9.12 / 55.35 ± 9.43	PCR-RFLP	6
Yong et al.	2010	China	Asian	Case-control	ACS	128 / 106	NR / NR	PCR-RFLP	5
Ghaderian et al.	2010	Iran	Asian	Case-control	ACS	400 / 200	NR / 65.8 ± 5.9	TaqMan	8
Zhi et al.	2010	China	Asian	Case-control	Stable	762 / 555	67.46 ± 9.61 / 69.90 ± 11.48	PCR-RFLP	8
Wang et al.	2011	China	Asian	Case-control	ACS	384 / 451	55.6 ± 10.9 / 54.1 ± 10.3	PCR-RFLP	8
Opstad et al.	2012	Norway	European	Case-control	Stable	996 / 204	62 / NR	TaqMan	8
Han et al.	2012	China	Asian	Case-control	Stable	91 / 101	NR / NR	PCR-RFLP	5
Saracini et al.	2012	Italy	European	Case-control	Stable	423 / 423	40–94 / 41–94	Nano gene electronic microchip technology	8
Spurthi et al.	2012	India	Asian	Case-control	Stable	100 / 100	56.73 ± 12.2 / 54.55 ± 14.38	PCR-RFLP	5
Sewelam et al.	2013	Egypt	African	Case-control	ACS	40 / 40	NR / NR	PCR-RFLP	5
Wu et al.	2013	China	Asian	Case-control	ACS	258 / 153	63.97 ± 12.32 / 63.61 ± 11.8	PCR-RFLP	7
Xu et al.	2013	China	Asian	Case-control	Stable	382 / 466	62 ± 12 / 62 ± 10	PCR-RFLP	8
Rodriguez et al.	2016	Mexico	American	Case-control	ACS	236 / 285	59 / 58	PCR-RFLP	8
Yin et al.	2016	China	Asian	Case-control	Stable	194 / 251	55.60 ± 10.42 / 56.21 ± 9.83	PCR-RFLP	7
Beton et al.	2016	Turkey	European	Case-control	Stable	200 / 200	60.2 ± 7.4 / 58.3 ± 7.7	PCR-RFLP	7
Daraei et al.	2016	Iran	Asian	Case-control	ACS	117 / 120	62.96 ± 12.80 / 52.55 ± 9.80	PCR-RFLP	6
El-Aziz et al.	2016	Egypt	African	Case-control	ACS	184 / 180	57.2 ± 10.9 / 58.8 ± 8.3	PCR-RFLP	7
Qin et al.	2016	China	Asian	case-control	Stable	261 / 261	58.75 ± 9.36 / 59.21 ± 10.10	PCR-RFLP	7
Peksiene et al.	2017	Lithuania	European	Case-control	ACS	518 / 645	61.9 ± 11.1 / 60.6 ± 11.9	TaqMan	8
Mahmoodi et al.	2017	Iran	Asian	case–control	Stable	100 / 100	59.4 ± 23.5 / 56.7 ± 29.5	PCR-RFLP	5
Xu et al.	2017	China	Asian	Case-control	Stable	264 / 186	59 ± 11.67 / 58 ± 10.72	PCR-RFLP	7
Makrygiannis et al.	2018	Greece	European	Case-control	Stable	175 / 166	72.7 ± 7.6 / 71.5 ± 7.1	PCR-RFLP	7
Malkani et al.	2019	Iran	Asian	Case-control	Stable	101 / 100	59.2 ± 10.2 / 47.3 ± 13.1	PCR-RFLP	5
MMP-9 (R279Q)
Nanni et al.	2007	Italy	European	Case-control	ACS	200 / 201	47.8 ± 6.2 / 47.0 ± 5.5	PCR-RFLP	7
Wu et al.	2009	China	Asian	Case-control	ACS	2506 / 687	NR / 60.42 ± 9.07	PCR-RFLP	8
Zhi et al.	2010	China	Asian	Case-control	Stable	762 / 555	67.46 ± 9.61 / 69.90 ± 11.48	PCR-RFLP	8
Wang et al.	2011	China	Asian	Case-control	ASC	384 / 451	55.6 ± 10.9 / 54.1 ± 10.3	PCR-RFLP	8
Mishra et al.	2012	India	Asian	Cohort	Stable	510 / 230	NR/ 54.2 ± 8.5	PCR-RFLP	8
Opstad et al.	2012	Norway	European	Case-control	Stable	994 / 204	62 / NR	TaqMan	8
Fiotti et al.	2017	Italy	European	Case-control	Stable	169 / 169	69–78 / 67–80	Sequencing	7
MMP-9 (P574R)
Zhi et al.	2010	China	Asian	Case-control	Stable	762 / 555	67.46 ± 9.61 / 69.90 ± 11.48	PCR-RFLP	8
Mishra et al.	2012	India	Asian	Cohort	Stable	510 / 230	NR / 54.2 ± 8.5	PCR-RFLP	8
MMP-9 (R668Q)
Zhi et al.	2010	China	Asian	Case-control	Stable	762 / 555	67.46 ± 9.61 / 69.90 ± 11.48	PCR–RFLP	8
Mishra et al.	2012	India	Asian	Cohort	Stable	510 / 230	NR / 54.2 ± 8.5	PCR–RFLP	8

NR, not reported; ACS, Acute coronary syndrome

Back to article page

ISSN: 1471-2261

Contact us

Submission enquiries: bmccardiovasculardisorders@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cardiovascular Disorders

Contact us